AstraZeneca's stock price rises due to positive results from COPD trial.

LootboxPhobia · 2026-03-27T10:50:01+00:00

AstraZeneca's stock price rose by 2.8% as its new drug tozorakimab achieved primary endpoints in Phase III clinical trials for chronic obstructive pulmonary disease (COPD), demonstrating the drug's ability to reduce the incidence of acute exacerbations with good tolerability and safety. The trial results will be released at the upcoming medical conference.

LootboxPhobia

2026-03-27 10:50:01

Abstract generation in progress

Investing.com - AstraZeneca Pharmaceuticals (ST:AZN) shares rose 2.8% on Friday, after the company said tozorakimab met its primary endpoint in two Phase 3 clinical trials for chronic obstructive pulmonary disease.

The pharmaceutical company reported positive results from the OBERON and TITANIA trials on Thursday, showing that, compared with placebo, tozorakimab reduced the annualized rate of moderate-to-severe COPD acute exacerbations in the prior smoker population and in the overall population.

According to the company, the drug was generally well tolerated, with good safety.

Use InvestingPro to track the latest developments in UK stocks

Tozorakimab is a monoclonal antibody that targets interleukin-33 (IL-33), inhibiting signal transduction of both the IL-33 reduced form and the oxidized form. These trials studied the drug’s effects in COPD patients who still experience acute exacerbations while receiving standard inhaled therapy. Patients received 300 mg of tozorakimab or placebo once every four weeks in addition to standard treatment.

Nearly 400 million people worldwide have been diagnosed with COPD, a progressive disease and the world’s third leading cause of death. More than 50% of patients still experience acute exacerbations even when receiving standard inhaled therapy, putting them at increased risk of cardiopulmonary events and death.

Both trials randomized a total of 2,306 patients, regardless of blood eosinophil count or smoking status, and covered all stages of lung function severity. The trials measured the annualized rate of moderate-to-severe COPD acute exacerbations over 52 weeks.

AstraZeneca Pharmaceuticals said that the full results of the OBERON and TITANIA trials will be presented at an upcoming medical meeting. Other Phase 3 trials of tozorakimab in the COPD area, PROSPERO and MIRANDA, are ongoing. The drug is also being studied in a Phase 3 trial for severe viral lower respiratory tract disease and a Phase 2 trial for asthma.

This article was translated with the assistance of artificial intelligence. For more information, please refer to our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.